30 Jun 2021Ended

Liquid Biopsy Detection of EGFR Mutations in NSCLC Patients Before and After Osimertinib Therapy


Estimated Turnout

upto 100
Based on previous editions


Jun 2021


Not Available
Claim event to edit details

Liquid biopsy is a useful tool for longitudinal monitoring of non-small cell lung cancer (NSCLC) patients, but requires highly sensitive and reliable .. Read more technologies for accurate detection of genomic alterations. In this webinar, Evi Lianidou of the University of Athens will discuss a study that evaluated digital PCR (dPCR) for detecting EGFR mutations in plasma cell-free DNA (cfDNA) and corresponding circulating tumor cell (CTC)-derived genomic DNA (gDNA). The study used Stilla’s Crystal Digital PCR in a group of EGFR-mutant NSCLC patients under osimertinib therapy at two time points: before treatment initiation and at progression of disease. Point-of-care tests have been available to clinicians and consumers for decades, but more recently, molecular testing technologies that can be used at the point of care are making inroads. For now, these molecular point-of-care tests are used largely for infectious disease testing, especially for the flu, and, more recently, COVID-19. But new technology developments are driving applications in new disease areas and end markets, including physician offices, emergency rooms, and CLIA-waived settings.

  • Share your Experience
  • Organizer
Logo Follow Company


USA115 Total Events / 1 Upcoming Event

More Events From The Organizer

You have no contacts. Please add contacts from below or share on social media

Send to all
No Results